Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial

CONCLUSION: Trastuzumab deruxtecan was not a cost-effective treatment option for patients with HER2-positive metastatic breast cancer in China. However, the use of trastuzumab deruxtecan may offer a cost-effective treatment alternative provided that its price is diminished.PMID:38039117 | DOI:10.1080/14737167.2023.2291157

Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 1, 2023 Category: Health Management Authors: Zhiwei Zheng Hongcai Chen Hongfu Cai Siqi Xu Source Type: research